Global Cardiovascular Drugs Market Overview, Trends and Drivers

Hypertension, rheumatic heart disease, ischemic heart disease, inflammatory heart disease, and cerebrovascular heart disease are some of the most common cardiovascular illnesses. Angina, hypertrophy, and heart failure are all major complications of hypertensive heart disease. High blood pressure in the heart's arteries and muscles promotes narrowing of the arteries, as well as thickening and enlargement of the heart.

The global cardiovascular drugs market is primarily driven by increased heart disease prevalence, as well as an ageing population and lifestyle-related disorders. Drugs for the treatment and prevention of cardiovascular disorders are needed to cater to the growing population suffering from these diseases. Another factor projected to drive the global cardiovascular drugs market is an increase in the number of diabetes patients. According to the American Diabetes Association, 30.3 million Americans (9.4% of the total population) had diabetes in 2015.

Cardiovascular Drugs Market

Trends:

Cardiovascular disease is one of the most common causes of death in the world. According to the American Heart Association, roughly 41.5 percent of the population in the United States had some type of cardiovascular disease in 2015, and this prevalence is expected to rise to 45 percent by 2035. The number of patients with cardiovascular illnesses is projected to rise as a result of sedentary lifestyles, changing food choices, and an increase in associated risk factors.

High blood pressure, high cholesterol, and smoking, according to the US Centers for Disease Control and Prevention (CDC), are all major risk factors for heart disease. At least one of these three risk factors affects over half of the population in the United States (47 percent). To combat the diseases, major firms are investing in the development of new treatments that are more effective and have fewer adverse effects.

 

Drivers:

Increase in number of cardiovascular disease:

The number of deaths from cardiovascular diseases is increasing as the world's population approaches 7 billion people and more people reach old age. Heart attacks, strokes, and other circulatory illnesses are among the main causes of premature death around the world. As a result, efforts to prevent and cure cardiovascular illnesses through medicine are increasing, resulting in a decreased death rate and more business for the cardiovascular drug industry.

In addition, there is a rise in cigarette use, poor diet and obesity, physical inactivity, and problematic alcohol consumption, all of which contribute to an increase in CVD and the need for medication.